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OBJECTIVE

The Diabetes Prevention Program (DPP) trial investigated rates of progression to
diabetes among adults with prediabetes randomized to treatment with placebo,
metformin, or intensive lifestyle intervention. Among women in the DPP, diabetes
risk reduction with metformin was greater in women with prior gestational diabetes mellitus (GDM) compared with women without GDM but with one or more
previous live births.
RESEARCH DESIGN AND METHODS

We asked if genetic variability could account for these differences by comparing
b-cell function and genetic risk scores (GRS), calculated from 34 diabetes-associated
loci, between women with and without histories of GDM.
RESULTS

b-Cell function was reduced in women with GDM. The GRS was positively associated with a history of GDM; however, the GRS did not predict progression to
diabetes or modulate response to intervention.
CONCLUSIONS

These data suggest that a diabetes-associated GRS is associated with development of GDM and may characterize women at risk for development of diabetes
due to b-cell dysfunction.
Diabetes Care 2014;37:909–911 | DOI: 10.2337/dc13-0700

In the Diabetes Prevention Program (DPP), women with prediabetes and prior
gestational diabetes mellitus (GDM) were 71% more likely to develop diabetes
compared with women without prior GDM and one or more previous live births.
Interestingly, intensive lifestyle intervention (ILS) was equally effective at
preventing progression to diabetes in both groups of women compared with
placebo (53 vs. 49% risk reduction), whereas metformin was more effective in
women with a history of GDM (50 vs. 14% risk reduction) (1). Individual genetic risk
scores (GRS), developed from a composite of single nucleotide polymorphisms
(SNPs) at loci associated with type 2 diabetes, predicted progression to diabetes
among DPP participants (2). Here, we compared b-cell function between GDM and
non-GDM women in the DPP and examined the utility of this GRS and its individual
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TYPE 2 DIABETES PREVENTION

Genetic Risk of Progression
to Type 2 Diabetes and Response
to Intensive Lifestyle or Metformin
in Prediabetic Women With
and Without a History of Gestational
Diabetes Mellitus

909

910

SNPs Associated With Gestational Diabetes

risk alleles in predicting progression to
diabetes and response to intervention in
women with or without prior GDM.
RESEARCH DESIGN AND METHODS

The DPP trial design and baseline
characteristics have been described in
detail previously (3,4). In brief, across 27
U.S. clinical centers, 3,234 participants
aged $25 years with impaired glucose
tolerance, elevated fasting glucose (95–
125 mg/dL), and BMI $24 kg/m2 were
randomized to placebo, metformin, or
ILS. Primary study end point was
development of diabetes. At the time of
enrollment, all women completed a
questionnaire regarding gravidity,
parity, and GDM history.
Among 1,416 women with one or more
live births and without GDM and 350
with a history of GDM, a subset (n 5
1,102 without GDM; n 5 281 with GDM)
underwent genotyping. DNA samples
were extracted from peripheral
leukocytes, and 34 type 2 diabetes–
associated SNPs were genotyped, as
described previously (2). A GRS for each
participant was calculated using the 34
loci by weighting each risk allele by its
effect size (b-estimate) on diabetes risk
and summing these values, with a
theoretical range of 0–68 (2).
Statistical Analyses

Similar numbers of GDM and non-GDM
women who underwent genotyping
were assigned to placebo, metformin, or
ILS (Table 1). Insulinogenic index
calculated from the 75-g, 2-h oral
glucose tolerance test [log(Δinsulin/
Δglucose)(0-30 min)] (5) was used as a
measure of b-cell function in general
linear models at baseline and at 1 year
to determine differences between GDM
and non-GDM women. Independent
variables included GDM status, race/
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ethnicity, age at randomization, parity,
and intervention (at 1 year only).
Logistic regression was used to evaluate
the association between GRS and
baseline history of GDM adjusted for
ethnicity, age, and parity. We examined
the GRS, treatment interventions, and
history of GDM in Cox regression models
as independent variables predicting
diabetes incidence. Models were
adjusted for ethnicity and parity. Next,
ANCOVA was used to assess the effect of
DPP treatments, GRS, and history of
GDM on b-cell function adjusted for
concomitant insulin sensitivity, as
measured by the oral disposition index
(DIo) (2,6) at 1 year. In contrast to the
insulinogenic index, DIo captures b-cell
function adjusted for insulin sensitivity
and therefore takes into account
physiological compensation (2,6).
Models were adjusted for baseline DIo,
ethnicity, age, and parity. Individual
effects of SNPs were tested in similar
ANCOVA models using SNP as an
additive term. Genotype, treatment,
and GDM three-way and two-way
interaction tests were performed for all
models testing postrandomization
outcomes. Treatment groups were
analyzed together if there were no
signiﬁcant interactions. Analyses were
also performed after adjustment for
waist circumference, which was a
signiﬁcant predictor of development of
diabetes in the DPP cohort (2). Nominal
two-sided P values are reported.
RESULTS

At baseline, b-cell function
(insulinogenic index) was decreased in
GDM (mean 4.19 [95% CI 4.10–4.29])
versus non-GDM (mean 4.35 [4.30–
4.40]) women (P , 0.01). At 1 year,
there was a signiﬁcant interaction
between treatment group and GDM

Table 1—b-Cell function [insulinogenic index: log(Δinsulin/Δglucose)(0–30 min)] at
1 year, after adjustment for baseline b-cell function, race/ethnicity, age
at randomization, and parity
Non-GDM*
n
Placebo

GDM*

Year 1 adjusted mean (95% CI) n Year 1 adjusted mean (95% CI) P value

394

5.16 (5.04–5.27)

93

4.73 (4.52–4.96)

0.164

Metformin 345

5.06 (4.99–5.14)

93

5.09 (4.93–5.26)

0.775

ILS

5.19 (5.77–8.36)

95

5.05 (4.89–5.22)

0.002

363

*Data are back transformed.

status (P 5 0.02); therefore, analysis
was stratiﬁed by GDM status and
treatment group. After adjustments,
1-year insulinogenic index was also
lower in GDM compared with non-GDM
women (P , 0.01) (Table 1).
Adjusted for ethnicity and age, the GRS
was positively associated with GDM
history (odds ratio 1.05 [95% CI 1.00–
1.08], P 5 0.04), such that for every one
unit increase in the GRS, the odds of
GDM increased by 5%. This association
was unaffected by additional
adjustment for parity (1.04 [1.00–1.08],
P 5 0.04); however, it was no longer
signiﬁcant after adjustment for waist
circumference (1.04 [1.00–1.08], P 5
0.07). There was no difference in the
hazard ratios (HRs) for the GRS
predicting progression to diabetes in
women with GDM compared with
women without GDM after adjustment
for ethnicity, age, and treatment arm
(P 5 0.09).
Because b-cell function as measured by
insulinogenic index was lower in GDM
than in non-GDM women, we next
examined the relationship of individual
SNPs within the GRS with b-cell function
after adjustment for concomitant
insulin sensitivity, as measured by DIo.
Four of the 34 SNPs comprising the GRS
are primarily associated with insulin
resistance (KLF14, rs972283; PPARG,
rs1801282; IRS1, rs7578326; GCKR,
rs780094) (7) and thus were excluded
from this analysis in order to isolate any
genetic component of b-cell function in
GDM women. After adjusting for
ethnicity, age, and parity, none of the
remaining 30 SNPs comprising the GRS
independently associated with DIo in
women with GDM compared with
women without GDM.
CONCLUSIONS

We found that among parous women in
the DPP, b-cell function deﬁned by
insulinogenic index was reduced in
women with a history of GDM compared
with women without prior GDM. This is
consistent with the reduced insulin-toglucose ratio previously reported in
GDM women in this cohort (1).
Further, a GRS calculated using SNPs
strongly associated with type 2 diabetes
was higher in women with GDM
compared with women without GDM;
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thus, GRS is positively associated with
prior GDM in DPP women. This
association remained signiﬁcant after
adjustment for age, ethnicity, and
parity, consistent with epidemiological
data demonstrating that increasing
parity or gravidity do not alter future
diabetes risk in women with (8) or
without (9) previous GDM who have
been pregnant.
On the other hand, these data suggest
the GRS is not associated with
progression to diabetes in high-risk
women either with or without a GDM
history, in any of the study arms. This is
of interest because a prior analysis from
the DPP showed that risk reduction for
progression to diabetes in response to
metformin was greater among women
with GDM compared with women
without GDM (1), leading us to
hypothesize that genetic variability may
play a role. Our data showed that GRS
predicted the presence of GDM but not
progression to diabetes among affected
women. That said, the HR for the GRS
predicting progression to diabetes in
this small cohort of female DPP
participants with prior GDM (HR 1.04
[95% CI 1.00–1.08]) is similar to the
signiﬁcant HR for the GRS predicting
progression to diabetes among the
entire DPP cohort with genetic
information (1.02 [1.02–1.03]) (2),
indicating that analysis of a larger
population of prediabetic women with
prior GDM may strengthen the
relationship between this GRS and
diabetes progression.
Limitations of our study include small
sample size and a relatively long
diabetes-free interval (mean 12 years)
since the index pregnancy among
women with GDM at enrollment. This
suggests the DPP excluded GDM women
with the highest risk for diabetes
progression, possibly diminishing
differences in GRS between women
with and without GDM.
b-Cell function is reduced in women
with GDM compared with women
without GDM. Accordingly, GRS
comprising 34 diabetes-associated loci
is higher in women with prediabetes and
histories of GDM compared with
women with prediabetes without GDM
and one or more prior live births. This

Sullivan and Associates

GRS does not, however, differentiate
diabetes risk or response to treatment
with metformin or ILS between high-risk
women with and without GDM.
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